Quantitative HER2 and p95HER2 levels in primary breast cancers and matched brain metastases

Neuro-Oncology

Volumn 17, Issue 9, 2015, Pages 1241-1249

  Duchnowska, Renata ^a   Sperinde, Jeff ^b   Chenna, Ahmed ^b   Huang, Weidong ^b   Weidler, Jodi M ^b   Winslow, John ^b   Haddad, Mojgan ^b   Paquet, Agnes ^b   Lie, Yolanda ^b   Trojanowski, Tomasz ^c   Mandat, Tomasz ^d   Kowalczyk, Anna ⁱ   Czartoryska Arłukowicz, Bogumiła ^e   Radecka, Barbara ^f   Jarosz, Bozena ^c   Staszkiewicz, Rafal ^g   Kalinka Warzocha, Ewa ^h   Chudzik, Małgorzata ^d   Biernat, Wojciech ⁱ   Jassem, Jacek ⁱ  

^a MILITARY INSTITUTE OF MEDICINE   (Poland)

^b MONOGRAM BIOSCIENCES   (United States)

^c MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^d INSTITUTE OF ONCOLOGY   (Poland)

^e Oncology Center of Bialystok   (Poland)

^f Opole Oncology Center   (Poland)

^g Ministry of Interior Affairs Hospital   (Poland)

^h Department of Oncology   (Poland)

ⁱ MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

brain metastasis; breast cancer; HER2; p95

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; P95HER2 PROTEIN; PROGESTERONE RECEPTOR; TRASTUZUMAB; UNCLASSIFIED DRUG; ERBB2 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; ASSAY; BRAIN METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HERMARK ASSAY; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OVERALL SURVIVAL; P95 VERATAG ASSAY; PRIMARY BREAST CANCER; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; BRAIN TUMOR; BREAST TUMOR; DISEASE FREE SURVIVAL; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; SECONDARY;

ADULT; AGED; BRAIN NEOPLASMS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; RECEPTOR, ERBB-2;

EID: 84940757399     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nov012     Document Type: Article

References (47)

1. Tsukada Y, Fouad A, Pickren JW, et al. Central nervous system metastasis from breast carcinoma. Autopsy study. Cancer. 1983; 52(12):2349-2354.
2. Amer MH. Chemotherapy and pattern of metastases in breast cancer patients. J Surg Oncol. 1982;19(2):101-105.
3. Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer. J Clin Oncol. 2004;22(17):3608-3617.
4. Pestalozzi BC, Zahrieh D, Price KN, et al. Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol. 2006;17(6):935-944.
5. Dawood S, Lei X, Litton JK, et al. Incidence of brainmetastases as a first site of recurrence among women with triple receptor-negative breast cancer. Cancer. 2012;118(19):4652-4659.
6. Musolino A, Ciccolallo L, Panebianco M, et al. Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer: epidemiological and clinical data from a population-based cancer registry study. Cancer. 2011;117(9): 1837-1846.
7. Duchnowska R, Szczylik C. Central nervous system metastases in breast cancer patients administered trastuzumab. Cancer Treat Rev. 2005;31(4):312-318.
8. Chien AJ, Rugo HS. Emerging treatment options for the management of brain metastases in patients with HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2013;137(1): 1-12.
9. Dawood S, Gonzalez-Angulo AM. Progress in the biological understanding and management of breast cancer-associated central nervous system metastases. Oncologist. 2013;18(6): 675-684.
10. Park IH, Ro J, Lee KS, et al. Trastuzumab treatment beyond brain progression in HER2-positive metastatic breast cancer. Ann Oncol. 2009;20(1):56-62.
11. Swain SM, Baselga J, Miles D, et al. Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA. Ann Oncol. 2014;25(6):1116-1121.
12. Scaltriti M, Nuciforo P, Bradbury I, et al. High HER2 expression correlates with response to the combination of lapatinib and trastuzumab. Clin Cancer Res. 2015;21(3):569-576.
13. Denkert C, Huober J, Loibl S, et al. HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer. Breast Cancer Res. 2013;15(1):R11.
14. Cheng H, Bai Y, Sikov W, et al. Quantitative measurements of HER2 and phospho-HER2 expression: correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab. BMC Cancer. 2014;14:326.
15. Scaltriti M, Rojo F, Ocana A, et al. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst. 2007;99(8): 628-638.
16. Sperinde J, Jin X, Banerjee J, et al. Quantitation of p95HER2 in paraffin sections by using a p95-specific antibody and correlation with outcome in a cohort of trastuzumab-treated breast cancer patients. Clin Cancer Res. 2010;16(16):4226-4235.
17. Duchnowska R, Sperinde J, Chenna A, et al. Quantitative measurements of tumoral p95HER2 protein expression in metastatic breast cancer patients treated with trastuzumab: independent validation of the p95HER2 clinical cutoff. Clin Cancer Res. 2014;20(10):2805-2813.
18. Pedersen K, Angelini PD, Laos S, et al. A naturally occurring HER2 carboxy-terminal fragment promotes mammary tumor growth and metastasis. Mol Cell Biol. 2009;29(12):3319-3331.
19. Angelini PD, Zacarias Fluck MF, Pedersen K, et al. Constitutive HER2 signaling promotes breast cancer metastasis through cellular senescence. Cancer Res. 2013;73(1):450-458.
20. Ward TM, Iorns E, Liu X, et al. Truncated p110 ERBB2 induces mammary epithelial cell migration, invasion and orthotopic xenograft formation, and is associated with loss of phosphorylated STAT5. Oncogene. 2013;32(19):2463-2474.
21. Huang W, Reinholz M, Weidler J, et al. Comparison of central HER2 testing with quantitative total HER2 expression and HER2 homodimer measurements using a novel proximity-based assay. Am J Clin Pathol. 2010;134(2):303-311.
22. Gancberg D, Di Leo A, Cardoso F, et al. Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol. 2002;13(7):1036-1043.
23. Wilking U, Karlsson E, Skoog L, et al. HER2 status in a population-derived breast cancer cohort: discordances during tumor progression. Breast Cancer Res Treat. 2011;125(2): 553-561.
24. Macfarlane R, Seal M, Speers C, et al. Molecular alterations between the primary breast cancer and the subsequent locoregional/metastatic tumor. Oncologist. 2009;17(2): 172-178.
25. Liedtke C, Broglio K, Moulder S, et al. Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann Oncol. 2009;20(12):1953-1958.
26. Thompson AM, Jordan LB, Quinlan P, et al. Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS). Breast Cancer Res. 2010;12(6):R92.
27. Hoefnagel LD, van de Vijver MJ, van Slooten HJ, et al. Receptor conversion in distant breast cancer metastases. Breast Cancer Res. 2010;12(5):R75.
28. Lindstrom LS, Karlsson E, Wilking UM, et al. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. J Clin Oncol. 2012;30(21): 2601-2608.
29. Curtit E, Nerich V, Mansi L, et al. Discordances in estrogen receptor status, progesterone receptor status, and HER2 status between primary breast cancer and metastasis. Oncologist. 2013;18(6): 667-674.
30. Gong Y, Han EY, Guo M, et al. Stability of estrogen receptor status in breast carcinoma: a comparison between primary and metastatic tumors with regard to disease course and intervening systemic therapy. Cancer. 2011;117(4):705-713.
31. Duchnowska R, Dziadziuszko R, Trojanowski T, et al. Conversion of epidermal growth factor receptor 2 and hormone receptor expression in breast cancer metastases to the brain. Breast Cancer Res. 2012;14(4):R119.
32. Gaedcke J, Traub F, Milde S, et al. Predominance of the basal type and HER-2/neu type in brain metastasis from breast cancer. Mod Pathol. 2007;20(8):864-870.
33. Grupka NL, Lear-Kaul KC, Kleinschmidt-DeMasters BK, et al. Epidermal growth factor receptor status in breast cancer metastases to the central nervous system. Comparison with HER-2/neu status. Arch Pathol Lab Med. 2004;128(9):974-979.
34. Yonemori K, Tsuta K, Shimizu C, et al. Immunohistochemical profiles of brain metastases from breast cancer. J Neurooncol. 2008;90(2):223-228.
35. Fuchs IB, Loebbecke M, Buhler H, et al. HER2 in brain metastases: issues of concordance, survival, and treatment. J Clin Oncol. 2002; 20(19):4130-4133.
36. Lear-Kaul KC, Yoon HR, Kleinschmidt-DeMasters BK, et al. Her-2/neu status in breast cancer metastases to the central nervous system. Arch Pathol Lab Med. 2003;127(11):1451-1457.
37. Kuukasjarvi T, Karhu R, Tanner M, et al. Genetic heterogeneity and clonal evolution underlying development of asynchronous metastasis in human breast cancer. Cancer Res. 1997;57(8): 1597-1604.
38. Niikura N, Liu J, Hayashi N, et al. Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. J Clin Oncol. 2012;30(6): 593-599.
39. Tsutsui S, Ohno S, Murakami S, et al. EGFR, c-erbB2 and p53 protein in the primary lesions and paired metastatic regional lymph nodes in breast cancer. Eur J Surg Oncol. 2002;28(4):383-387.
40. Taucher S, Rudas M, Mader RM, et al. Influence of neoadjuvant therapy with epirubicin and docetaxel on the expression of HER2/neu in patients with breast cancer. Breast Cancer Res Treat. 2003;82(3):207-213.
41. Vincent-Salomon A, Jouve M, Genin P, et al. HER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic process. Cancer. 2002;94(8):2169-2173.
42. Saez R, Molina MA, Ramsey EE, et al. p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer. Clin Cancer Res. 2006;12(2):424-431.
43. Parra-Palau JL, Morancho B, Peg V, et al. Effect of p95HER2/611CTF on the response to trastuzumab and chemotherapy. J Natl Cancer Inst. 2014;106(11):dju291.
44. Sperinde J, Huang W, Vehtari A, et al. Quantitative p95HER2 and HER2 correlations with outcome in the FinHer trial. Cancer Res. 2014;74(24-Supplement):P3-06-03.
45. Scaltriti M, Chandarlapaty S, Prudkin L, et al. Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor. Clin Cancer Res. 2010;16(9): 2688-2695.
46. Bachelot T, Romieu G, Campone M, et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol. 2013; 14(1):64-71.
47. Parra-Palau JL, Pedersen K, Peg V, et al. A major role of p95/611-CTF, a carboxy-terminal fragment of HER2, in the downmodulation of the estrogen receptor in HER2-positive breast cancers. Cancer Res. 2010;70(21):8537-8546.